anti-notch4 monoclonal antibodies clone hmn4-14 (Bio X Cell)
Structured Review

Anti Notch4 Monoclonal Antibodies Clone Hmn4 14, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-notch4 monoclonal antibodies clone hmn4-14/product/Bio X Cell
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Breast Cancer Macrophage Heterogeneity and Self-renewal are Determined by Spatial Localization"
Article Title: Breast Cancer Macrophage Heterogeneity and Self-renewal are Determined by Spatial Localization
Journal: bioRxiv
doi: 10.1101/2023.10.24.563749
Figure Legend Snippet: ( a ) Macrophages plated either directly with oTME cells (cell contact) or separated by transwells for 7 days, followed by 72 hrs of EdU labeling. Macrophages were imaged (mT) at plating and prior to flow cytometry analysis of EdU. Individual dots represent individual fields of view from 3 independent experiments. Data are shown as mean±SD, 2-tailed t-test. Scale bar, 100μm. ( b ) Gene Set Enrichment Analysis of Gene Ontology showing a significant enrichment of Notch signaling pathway in oTME macrophages (GO:0007219; FDR=0.00065; top, enrichment scores; bottom, rank positions of member genes). ( c ) Rosa26 mTmG mice (n=8) with established mammary tumors were treated with Notch4 monoclonal antibodies (15μg/kg body weight, dosed every 3 days, intraperitoneally) or vehicle (PBS) as a control for 20 days. Tumor sizes were recorded by a caliper and shown as mean ±SD, 2-way ANOVA test, Bonferroni-corrected. At the trial endpoint, mammary tumors were imaged (right). ( d ) Macrophage proliferation analysis in mammary tumors from ( c ) following Notch4 treatment (n=6) at study endpoint. Tumors were harvested and scored for Ki67 and CD206 expression in macrophages by flow cytometry. Data are shown as mean±SD, 2-way ANOVA test, Bonferroni-corrected. Macrophage abundance quantified as percent of live CD45+ cells. Data are shown as mean±SD, Mann-Whitney test. ( e ) C57BL/6 female mice were injected with luciferase-expressing HGSOC cells (1 x 10 6 , intraperitoneally) and treated 7 days after tumor BLI signals were established with NOTCH4 or isotype control IgG antibodies (15μg/kg body weight, dosed every 3 days, intraperitoneally). BLI measurements were recorded every week and representative images are presented.
Techniques Used: Labeling, Flow Cytometry, Bioprocessing, Control, Expressing, MANN-WHITNEY, Injection, Luciferase
Figure Legend Snippet: ( a ) Immunoblotting for the cleaved Notch intracellular domain (NICD), ARG1, phospho-PI3K (pAKT), and phospho-MAPK (pERK), confirming active Notch and PI3K pathways in oTME macrophages but not in CSF-1 macrophages. ( b ) Impact of γ-secretase inhibition on proliferation of oTME macrophages. BM monocytes were isolated and plated with oTME cells for 7 days and then were treated with either compound-E (CompE; 10μM) or DMSO as a control for additional 10 days. Macrophages and oTME cells were analyzed by flow cytometry for Ki67 expression. Data (n=3) are shown as mean±SD, Welch’s t- test. ( c ) EdU incorporation in BMDMs following treatment with Adam17 protease inhibitor (A17Pro) or PBS as vehicle control. Cells were plated with oTME cells in the presence of A17Pro or PBS and cultured for seven days. Cell cultures were then labeled with EdU for 48hrs and were analyzed by flow cytometry for EdU incorporation (n=4 replicates). Data are shown as mean±SD, Welch’s t-test. MFI; mean fluorescence intensity. ( d ) Flow cytometry of relative abundances of Ki67+ tumor cells (mT neg CD45 neg ), total immune cells (mT+ CD45 + ), and stromal cells (mT+ CD45 neg ) in control vs. NOTCH4-treated tumors (n=6 replicates). Data are shown as mean ±SD, 2-way ANOVA test, Bonferroni-corrected. ( e ) Immunofluorescence staining of CD31, IBA1, and Ki67 in tumor transplants from (a). Scale bars, 100μm. ( f ) Primary tumor growth (left) and lung metastasis (right) of metastatic TNBC PDX cells (BR18) in NSG mice following NOTCH4 and IgG treatment. Mice were engrafted with 50K cells and treated as in ( c). Growth kinetics and lung dissemination were evaluated by bioluminescence.
Techniques Used: Western Blot, Inhibition, Isolation, Control, Flow Cytometry, Expressing, Protease Inhibitor, Cell Culture, Labeling, Fluorescence, Immunofluorescence, Staining
Figure Legend Snippet: ( a ) S patial P r O tein and T ranscriptome S equencing (SPOTS) on tissue from MMTV-PyMT model (n=3 mice). ( b ) Tissue structure. IF staining with EpCAM-PE and CD45-APC to reveal the tissue architecture. Scale bar, 200μm. ( c ) Spatial clustering and ADT signatures of each cluster. Left panel: spatially-informed clusters (1-6) overlaid onto tissue spatial barcodes. Right panel: heatmap of ADT expression for each cluster, where the right colorbar represents the cell-type annotation of each ADT. ( d ) Spatial ADT expression levels of key surface markers for tumor (EpCAM), fibroblasts (PDPN), and macrophages (F4/80, CD86) in fibroblast-enriched region (cluster 2) and adenocarcinoma (cluster 5). Note enrichment of EpCAM high CD86 high expression in adenocarcinoma region (cluster 5; consistent with TNMs) vs. enrichment of PDPN high F4/80 high expression in fibroblasts-enriched regions (cluster 2; consistent with SAMs). ( e ) Spatial correlation of lineage (NK1.1, CD4, CD8, CD11b, F4/80, MHC-II, EpCAM) immunostimulatory (CD27, CD86, CCR2, CD11c), and immunosuppressive (PD-L1, Sca-1) ADTs in fibroblast-enriched region (cluster 2) and adenocarcinoma region (cluster 5). ADTs are colored by bivariate Moran’s I (color scale). The size of each dot represents the inverse of standard error of the mean (S.E.M; n=3 mice). Dendrograms indicate the hierarchical clustering of the ADTs. ( f ) EpCAM and CCR2 vs. PDPN and F4/80 ADTs co-expression levels overlaid onto tumor sample A tissue (Methods) and immunophenotyping of SAMs and TNMs. Middle panel: boxplots of EpCAM and CCR2 vs. PDPN and F4/80 co-expression levels (addition of EpCAM and CCR2, or PDPN and F4/80 expression values). Right panel: violin plots of immune-stimulatory and suppressive ADT expression levels. Kolmogorov–Smirnov test, * P < 0.05, ** P < 0.01, *** P < 0.001, otherwise not significant (n.s). Each boxplot ranges from the first and third quartiles with median values shown as middle lines, and the whiskers represent 1.5 times the interquartile range. ( g ) Volcano plot showing log fold changes (logFC) of top 5,000 most variable genes between fibroblast-enriched region (cluster 2) vs. adenocarcinoma region (cluster 5) and their significance (y axis; -log10 scale). Genes are dotted and colored by logFC levels (color scale). The size of each dot represents the difference in the fraction of detection between the two groups. Macrophage-related genes are annotated. P -values were determined by Wilcoxon Rank Sum test. Vertical dotted lines represent ±0.2 logFC. Horizontal dotted lines represent FDR of 0.05 (-log10 scale). Raw, FDR corrected P -values, and logFC values are listed in Supplementary Table 10. ( h ) Gene Set Enrichment Analysis of scRNA-seq Ly6a +SAM gene signature (Supplementary Table 7; ) in the fibroblast-enriched region (cluster 2) ( P = 0.002). ( i ) Gene expression of IFNα response genes ( Ly6a, Ly6c1, Ifit1, Ifit3, Ifitm3, Irf7, Isg15, Stat1, Stat2 ) in SAMs (cluster 2) and TNMs (cluster 5). Genes are dotted and colored by expression levels. The size of each dot represents the percentage of expression in the tissue area. ( j ) Notch signaling pathway activity in fibroblast-enriched regions (SAMs) and adenocarcinoma regions (TNMs) across all three biological replicates. Left panel: violin plots of NOTCH4 ADT expression levels. Right panel: violin plots of Notch signaling pathway (GO:0007219; n=179 genes) transcriptional expression levels. Kolmogorov–Smirnov test, * P < 0.05, ** P < 0.01, *** P < 0.001, otherwise not significant (n.s).
Techniques Used: Staining, Expressing, Gene Expression, Activity Assay



